If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Caribou Biosciences, Inc. (CRBU)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying their novel CRISPR platform, CRISPR hybrid RNA-DNA, or chRDNA, pronounced “chardonnay,” toward the development of next-generation, genome-edited cell therapies. Their renowned founders, including a Nobel laureate, are pioneers in CRISPR genome editing. Their chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, which enables them to perform multiple, precise genomic edits, while maintaining genomic integrity. They believe that their technology has broad potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell therapies, cell therapies derived from genome-edited iPSCs, and in vivo genome-editing therapies. The genome-editing technologies currently used in the allogeneic cell therapy field generally have limited efficiency, specificity, and versatility for performing the multiple, precise genomic edits necessary to address insufficient persistence. Their chRDNA technology is designed to address these genome-editing limitations and improve cell therapy activity. By applying this approach to allogeneic cell therapies, they believe they can unlock their full potential by improving upon their effectiveness and durability.
Biological Products (no Diagnostic Substances)
Rachel E. Haurwitz Jason V. O’Byrne
Employees Founded
76 2011


Address: 2929 7th Street, Suite 105, Berkeley, California 94710. Us

Telephone: (510) 982-6030

Web page:

IPO information

First Trade Date 7/23/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 13.5
Shares Revised (MM) 19
Expected offer amount (MM) $202.5
Realized offer amount(MM) $304

Financial Data (last reporting year)

Market Cap (MM) $820.65
Revenues (MM) $12.3
Net Income (Loss) (MM) $-37.7


What do you think will happen with the CRBU share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: BofA Securities

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
BofA Securities/ Citigroup/ SVB Leerink

Sector: Healthcare

Tweets about $CRBU

Tweets volume:

RT volume:


Google Trends Stats